Publications and presentations

AVEO Oncology allows you to access a number of published papers and presentations outlining our clinical data that were given at premier conferences and symposia around the world.

June 11, 2020
PublicationFiclatuzumab

A Multicentre Phase I Study of Ficlatuzumab and Cetuximab in Cetuximab-Resistant, Recurrent/Metastatic Head and Neck Cancer

Authors: Julie E. Bauman, James Ohr, William E. Gooding, Robert L. Ferris, Umamaheswar Duvvuri, Seungwon Kim, Jonas T. Johnson, Adam C. Soloff, Gerald Wallweber, John Winslow, Autumn Gaither-Davis, Jennifer R. Grandis, Laura P. Stabile. Click here for link to article.

May 29, 2020
PresentationTivozanib

ASCO 2020: TIVO-3: Final OS analysis of a randomized, controlled, multi-center, open-label phase 3 study to compare tivozanib to sorafenib in subjects with metastatic renal cell carcinoma (RCC)

January 27, 2020
PresentationFiclatuzumab

ASCO GI 2020: Phase 1b Study of Gemcitabine, Nab-paclitaxel, and Ficlatuzumab in Patients with Advanced Pancreatic Cancer

December 24, 2019
PublicationTivozanib

Real-World Results from One Year of Therapy with Tivozanib

Authors: Michael Staehler, Annabel K. Spek, Severin Rodler, Melanie Schott, Jozefina Casuscelli, Lena Mittelmeier, Marcus Schlemmer. Click here for link to article.

November 16, 2019
PresentationTivozanib

KCS 2019: TIVO-3: A Phase 3 Study to Compare Tivozanib to Sorafenib in Subjects with Refractory Advanced Renal Cell Carcinoma (RCC): Overall Survival 2-Year Update

September 30, 2019
PresentationTivozanib

ESMO 2019: TiNivo: Tivozanib Combined With Nivolumab Results in Prolonged Progression-Free Survival in Patients with Metastatic Renal Cell Carcinoma (mRCC) – Final Results

1 … 4 5 6 7 8 … 15

Looking for medical information? Contact our Medical Information Team at

AVEOmedicalinformation@aveooncology.com.